These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 10873062)

  • 1. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential effects of mutant p53 alleles on advanced murine lung cancer.
    Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T
    Cancer Res; 2005 Nov; 65(22):10280-8. PubMed ID: 16288016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
    Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
    Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 transdominance but no gain of function in mouse brain tumor model.
    Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
    Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 gene and its role in human brain tumors.
    Bögler O; Huang HJ; Kleihues P; Cavenee WK
    Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
    Dearth LR; Qian H; Wang T; Baroni TE; Zeng J; Chen SW; Yi SY; Brachmann RK
    Carcinogenesis; 2007 Feb; 28(2):289-98. PubMed ID: 16861262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival.
    Iwamoto KS; Mizuno T; Ito T; Tsuyama N; Kyoizumi S; Seyama T
    Cancer Res; 1996 Sep; 56(17):3862-5. PubMed ID: 8752146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas.
    Kakinuma S; Nishimura M; Kubo A; Nagai JY; Amasaki Y; Majima HJ; Sado T; Shimada Y
    Mutat Res; 2005 May; 572(1-2):132-41. PubMed ID: 15790496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
    Baxter EW; Blyth K; Cameron ER; Neil JC
    J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
    Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
    Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.